| Date | Insider | Role | Type | Shares | Price | Value |
|---|---|---|---|---|---|---|
| 2026-09-14 | Meeker David P | director, officer | Option exercise | 50,000 | $6.05 | $303K |
| 2026-09-14 | Meeker David P | director, officer | Sale | 6,439 | $101.75 | $655K |
| 2026-09-14 | Meeker David P | director, officer | Sale | 30,746 | $102.35 | $3.15M |
| 2026-09-14 | Meeker David P | director, officer | Sale | 8,698 | $103.43 | $900K |
| 2026-09-14 | Meeker David P | director, officer | Sale | 1,817 | $104.55 | $190K |
| 2026-09-14 | Meeker David P | director, officer | Sale | 2,300 | $105.19 | $242K |
| 2026-08-13 | Lee Jennifer Kayden | officer | Option exercise | 35,000 | $24.29 | $850K |
| 2026-08-13 | Lee Jennifer Kayden | officer | Option exercise | 21,601 | $6.80 | $147K |
| 2026-08-13 | Lee Jennifer Kayden | officer | Sale | 75,834 | $117.38 | $8.90M |
| 2026-08-12 | Mazabraud Yann | officer | Option exercise | 46,625 | $6.80 | $317K |
| 2026-08-12 | Mazabraud Yann | officer | Sale | 2,300 | $111.80 | $257K |
| 2026-08-12 | Mazabraud Yann | officer | Sale | 1,000 | $112.86 | $113K |
| 2026-08-12 | Mazabraud Yann | officer | Sale | 3,605 | $114.70 | $413K |
| 2026-08-12 | Mazabraud Yann | officer | Sale | 14,568 | $115.43 | $1.68M |
| 2026-08-12 | Mazabraud Yann | officer | Sale | 18,208 | $116.49 | $2.12M |
| 2026-08-12 | Mazabraud Yann | officer | Sale | 17,319 | $117.47 | $2.03M |
| 2026-04-01 | Mazabraud Yann | officer | Option exercise | 12,875 | — | — |
| 2026-04-01 | Popovits Kimberly J | director | Award | 6,808 | — | — |
| 2026-04-01 | Popovits Kimberly J | director | Award | 10,257 | $88.12 | $904K |
| 2026-04-01 | Mazabraud Yann | officer | Option exercise | 10,375 | — | — |
| 2026-04-01 | Mazabraud Yann | officer | Option exercise | 2,500 | — | — |
| 2026-03-12 | Mathers Edward T | director | J | 4,199 | — | — |
| 2026-03-04 | German Christopher Paul | officer | Option exercise | 1,500 | $17.97 | $27K |
| 2026-03-04 | German Christopher Paul | officer | Sale | 5,614 | $89.56 | $503K |
| 2026-03-02 | Mazabraud Yann | officer | Award | 35,000 | $94.94 | $3.32M |
| Filed | Form | Filer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-10-13 | SCHEDULE 13G | JPMORGAN CHASE & CO | — | — | view → |
| 2020-06-26 | SC | MPM BIOVENTURES V, L.P. | — | — | view → |
| 2020-02-05 | SC | MPM BIOVENTURES V, L.P. | — | — | view → |
| 2019-02-12 | SC | MPM BIOVENTURES V, L.P. | — | — | view → |
| Filed | Form | Issuer | Stake | Shares | |
|---|---|---|---|---|---|
| 2026-10-08 | SCHEDULE 13D/A | ArriVent BioPharma, Inc. | 5.80% | 2,875,962 | view → |
| 2026-10-02 | SCHEDULE 13D | ADARx Pharmaceuticals, Inc. | 14.00% | 14,913,764 | view → |
| 2026-09-25 | SCHEDULE 13D | Electra Therapeutics, Inc. | 11.00% | 6,885,170 | view → |
| 2026-09-10 | SCHEDULE 13D/A | Braveheart Bio, Inc. | 13.50% | 12,175,159 | view → |
| 2026-08-18 | SCHEDULE 13D | BlossomHill Therapeutics, Inc. | 8.90% | 2,714,279 | view → |
| 2026-08-18 | SCHEDULE 13D | Braveheart Bio, Inc. | 17.20% | 12,175,159 | view → |
| 2026-08-10 | SCHEDULE 13D/A | MBX Biosciences, Inc. | — | 3,074,853 | view → |
| 2026-08-05 | SCHEDULE 13D | Yarrow Bioscience, Inc. | 9.97% | 266,306 | view → |
| 2026-07-29 | SCHEDULE 13D | Scribe Therapeutics, Inc. | 7.20% | 1,348,825 | view → |
| 2026-07-20 | SCHEDULE 13D/A | Q32 Bio Inc. | — | 4,127,987 | view → |
| 2026-06-24 | SCHEDULE 13D/A | Enliven Therapeutics, Inc. ELVN | — | 6,774,507 | view → |
| 2026-06-17 | SCHEDULE 13D/A | Enliven Therapeutics, Inc. ELVN | 10.93% | 7,634,630 | view → |
| 2026-06-15 | SCHEDULE 13D/A | Shattuck Labs, Inc. STTK | — | 9,021,127 | view → |
| 2026-06-01 | SCHEDULE 13D/A | Q32 Bio Inc. QTTB | — | 4,127,987 | view → |
| 2026-04-10 | SCHEDULE 13D/A | Adicet Bio, Inc. ACET | 8.80% | 844,787 | view → |
| 2026-01-27 | SCHEDULE | Corvus Pharmaceuticals, Inc. CRVS | 10.30% | 8,609,091 | view → |
| 2025-10-10 | SCHEDULE | Adicet Bio, Inc. ACET | 9.60% | 14,772,598 | view → |
| 2025-09-30 | SCHEDULE | MBX Biosciences, Inc. MBX | 9.00% | 4,002,887 | view → |
| 2025-07-21 | SCHEDULE | Passage BIO, Inc. PASG | 7.82% | 243,878 | view → |
| 2025-05-14 | SCHEDULE | Corvus Pharmaceuticals, Inc. CRVS | 12.20% | 9,785,423 | view → |
Full feed access · API · daily intelligence brief · custom alerts. From $49/mo.
See pricing →